scholarly journals Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy

1985 ◽  
Vol 28 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Manuel Praga ◽  
Victor Gutierrez-Millet ◽  
José J. Navas ◽  
Luis M. Ruilope ◽  
José M. Morales ◽  
...  
Keyword(s):  
Renal Function ◽  
Iga Nephropathy ◽  
Macroscopic Hematuria

scholarly journals Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function

2011 ◽  
Vol 12 (1) ◽  
Author(s):  
Kisara Onda ◽  
Isao Ohsawa ◽  
Hiroyuki Ohi ◽  
Mariko Tamano ◽  
Satoshi Mano ◽  
...  
Keyword(s):  
Renal Function ◽  
Iga Nephropathy ◽  
Complement Proteins ◽  
Activation Marker

IgA Nephropathy: Association of a History of Macroscopic Hematuria Episodes with Increased Production of Polymeric IgA

Nephron ◽  
1987 ◽  
Vol 45 (2) ◽  
pp. 98-103 ◽  
Author(s):  
Luz Lozano ◽  
Rosa García-Hoyo ◽  
Jesús Egido
Keyword(s):  
Iga Nephropathy ◽  
Macroscopic Hematuria ◽  
History Of

Therapeutic Approach for the Deteriorated Renal Function in IgA Nephropathy

1991 ◽  
pp. 84-86
Author(s):  
K. Fukushi ◽  
H. Yamabe ◽  
K. Ozawa ◽  
H. Ohsawa ◽  
N. Chiba ◽  
...  
Keyword(s):  
Renal Function ◽  
Iga Nephropathy ◽  
Therapeutic Approach

scholarly journals Tonsillectomy in IgA Nephropathy - Clinical Case

2021 ◽  
Vol 26 (3) ◽  
pp. 59-61
Author(s):  
Livia Mirela Popa ◽  
Livia Popa ◽  
Cătălin-Bogdan Osalciuc
Keyword(s):  
Antibiotic Therapy ◽  
Iga Nephropathy ◽  
Clinical Case ◽  
Acute Infection ◽  
Acute Onset ◽  
First Episode ◽  
Urinary Volume ◽  
Upper Airways ◽  
Macroscopic Hematuria ◽  
Nephritic Syndrome

Abstract This article presents the clinical case of IgA nephropathy of a patient hospitalized in order to investigate a nephritic syndrome, apparently with acute onset, discovered in the following circumstances: recurrent macroscopic hematuria, decreased urinary volume, the first episode occurring about a month ago in the context of an acute infection of upper airways, remitted under antibiotic therapy, with reappearance every 2 weeks, also accompanied by odynophagia and decreased urinary volume.

scholarly journals Indian scenario of IgA nephropathy: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
pp. 159-65
Author(s):  
Anju Khairwa
Keyword(s):  
Systematic Review ◽  
Iga Nephropathy ◽  
Clinical Features ◽  
Meta Analysis ◽  
Microscopic Hematuria ◽  
Macroscopic Hematuria ◽  
Female Ratio ◽  
Cochrane Database ◽  
Male Female Ratio ◽  
Indian Scenario

Background: IgA nephropathy (IgAN) is most common primary glomerulopathy. There are variations in prevalence of IgAN and its clinical features in different studies from India. Aim: To summarize overall scenario of IgAN in India. Methods: In this systematic review, studies related to IgAN and related renal disease were included. Data searched were PubMed, EMBASE, Google scholar, and Cochrane Database from inception to 31st January 2019. Results: Total 49 studies (N=2480) were included: 21studies (N=2309) of primary IgAN; 19 studies (N=21) of Secondary IgAN; four studies (N=133) of IgA vasculitis nephropathy (IgAVN); and five studies (N=17) of IgA dominant nephropathy (IgADN). Prevalence of IgAN was 16.5% in India. Age of affected persons was ranging from 27.2±16.7 to 48.6±21.3 years . Male female ratio was 1.8:1. Clinical features of Primary IgAN, IgAVN, IgADN & Secondary IgAN were microscopic hematuria (49.6%, 44.4%, 15.6% & 59.5%), macroscopic hematuria (5.1%, 0.4%,40.9%,& 35.7%), Subnephrotic proteinuria (42.1%, 29.4%, 23.2%, & 52.3%), nephrotic proteinuria (16.0%, 4.4%, 76.8%,& 47.6%), and hypertension (25.8%,18.3%, 35.5%,& 47.6%).. The 24 hours proteinuria was ranging from 2.6±1.5 to 4.7±2.3 gm/day and serum creatinine (mg/dl) was ranging from 0.9±0 to 3.5±3.9 mg/dl. Histolomorphologically, all type of IgAN showed mesangial hypercellularity and Immunofluorescence revealed IgA deposition. Conclusion: The overall prevalence of primary IgAN in India was 16.5%. The subnephrotic proteinuria and microscopic hematuria were common clinical features. Keywords: IgA Nephropathy; histomorphology; prevalence; India.

scholarly journals Immunoglobulin A Nephropathy as the First Clinical Presentation of Wilson Disease: A Case Report and Literature Review

2021 ◽  
Author(s):  
Yong-Zhe Zhang ◽  
Geng Jian ◽  
Ping He ◽  
Rui Yu ◽  
Mi Tian ◽  
...  
Keyword(s):  
Renal Function ◽  
Iga Nephropathy ◽  
Wilson Disease ◽  
Genetic Disorder ◽  
Immunoglobulin A ◽  
Elevated Serum ◽  
Clinical Manifestations ◽  
Kidney Injury ◽  
Copper Metabolism ◽  
Normal Liver

Abstract Background: Wilson disease (WD) is a rare genetic disorder of copper metabolism. The difference in copper tissue accumulation lead to various clinical manifestations, including some atypical presentations. The complex clinical picture makes it easy to miss and misdiagnose, even delay the best chance for treatment. Case presentation: A 26-year-old male patient who had nephritis-range proteinuria and elevated serum creatinine. The renal pathology indicated Immunoglobulin A (IgA) nephropathy and tubular injury which was inconsistent with glomerular lesions. Cirrhosis was also detected by imaging examination. Considering both kidney injury and liver damage, WD was suspected. According to further detected results of abnormal copper metabolism, corneal Kayser-Fleischer rings(K-F rings), and genetic disorder of ATP7B gene, he was finally diagnosed as a case of WD.The patient was given oral penicillamine and zinc sulfate daily and he was also prescribed losartan to control proteinuria on the premise of monitoring renal function and blood pressure. During the 2 years follow-up, the patient’s 24h uric cooper dropped to normal. The sign of tremor hands disappeared. The Urine protein and renal function keep stable. The patient had normal liver function and maintained good quality of daily life. Conclusions: In some cases, IgA nephropathy patients with suspicious and unexplained neurological and liver symptoms cannot be ignored. They may eventually be diagnosed with WD.

scholarly journals Dabigatran-induced anticoagulant-related nephropathy with undiagnosed IgA nephropathy in a patient with normal baseline renal function

2019 ◽  
Vol 8 (4) ◽  
pp. 292-296 ◽  
Author(s):  
Masaki Ikeda ◽  
Mari Tanaka ◽  
Saeko Shimoda ◽  
Hirona Saita ◽  
Seira Nishikawa ◽  
...  
Keyword(s):  
Renal Function ◽  
Iga Nephropathy ◽  
Baseline Renal Function

P0430EFFECT OF CORTICOSTEROIDS THERAPY FOR PATIENTS OF IGA NEPHROPATHY WITH CRESCENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Mengjun Liang ◽  
Aihua Li ◽  
Zongpei Jiang
Keyword(s):  
Renal Function ◽  
Side Effects ◽  
Iga Nephropathy ◽  
Steroid Therapy ◽  
Oral Prednisone ◽  
Pulse Therapy ◽  
The Other ◽  
Intravenous Methylprednisolone ◽  
Steroid Pulse ◽  
Renal Function Deterioration

Abstract Background and Aims Patients with IgA nephropathy (IgAN) presented proteinuria≥1g/d and eGFR≥50ml/min/1.73m2 after supportive treatment had been advised 6-month course of corticosteroids therapy. Update of Oxford classification of IgAN had recommended crescents be added to the MEST score for they were predictive of outcome. Whether we should take some more positive therapy for crescents? Method We conducted a single-center, retrospective cohort study enrolling 46 patients from 2017.01 to 2018.06, diagnosed with IgAN by renal biopsy. Eligible patients had proteinuria of 0.5∼3.5g/d, eGFR≥30ml/min/1.73m2 and crescent proportion <50%. Patients were divided into two groups, one for classical steroid treatment (intravenous methylprednisolone 0.25g/d for 3 days at the beginning of months 1, 3 and 5, plus oral prednisone 0.5 mg/kg/d for 6 months, called 1-3-5 Group) and the other assigned an optimized steroid therapy (intravenous methylprednisolone 0.25g/d for 3 days at the beginning of months 1, 2 and 3, plus oral prednisone 0.5 mg/kg/d for 6 months, called 1-2-3 Group). The primary endpoint was remission of proteinuria, secondary endpoint was deterioration in renal function. Results There were 23 patients in each group and no significant differences in age, gentle, baseline proteinuria and eGFR between the two groups, except for the proportion of crescents (for Oxford C1 and C2: 52.5% and 13% in 1-3-5 Group vs. 95.7% and 4.3% in 1-2-3 Group respectively, p=0.001). After 6 months therapy, proteinuria in 1-3-5 Group was 0.5(0.2,0.8)g/d (vs. 1.2(0.8,2.6)g/d at baseline, p <0.001) and that in 1-2-3 Group was 0.3(0.2,0.6)g/d (vs. 1.5(0.7,2.6)g/d at baseline, p <0.001). 78.3% of patients in 1-3-5 Group had got remission of proteinuria, while 95.7% in 1-2-3 Group (p=0.187). The 6th month eGFR in 1-3-5 Group was 80.7(59.8,116.2)ml/min/1.73m2 (vs. 77.5(54.8,104.6)ml/min/1.73m2 at baseline, p=0.212), while that in 1-2-3 Group was 97.8(68.6,130.9)ml/min/1.73m2 (vs. 79.5(52.9,108.7)ml/min/1.73m2 at baseline, p=0.002). The slope of eGFR in 1-3-5 Group was 0.7(-1.7,3.3)ml/min/1.73m2/month, while that in 1-2-3 Group was 3(1.2,5.4)ml/min/1.73m2/month, p=0.027. For side effects, two patients in 1-2-3 Group had met bronchitis during the 2nd and 3rh therapy-month respectively; in 1-3-5 Group, one patient had got glaucoma during the 2nd therapy-month and the other had happened steroid-induced diabetes mellitus during the 3rd therapy-month. Conclusion Our preliminary results had indicated that optimized steroid therapy had equal effect on reducing proteinuria but more significant advantage to protect against renal function deterioration in IgAN with crescents. 1-2-3 month-steroid pulse therapy had not increase the morbidity of irreversible or severe side effects.

Sign in / Sign up

Export Citation Format

Share Document